More Net giants deal in shady drug ads
Selpercatinib is the first drug from Loxo’s pipeline that Lilly has brought to market. Prior to the acquisition, Loxo won approval of Vitrakvi, which targets a different genetic mutation and is sold by Bayer AG. The teams’ former medic, who is currently facing a fit-to-practise tribunal, paints a stark picture of the gold-medal factory across…